Revista Espanola de Cardiologia Suplementos最新文献

筛选
英文 中文
Introducción 导言
Revista Espanola de Cardiologia Suplementos Pub Date : 2017-01-01 DOI: 10.1016/S1131-3587(19)30016-0
Juan M. Ruiz-Nodar
{"title":"Introducción","authors":"Juan M. Ruiz-Nodar","doi":"10.1016/S1131-3587(19)30016-0","DOIUrl":"https://doi.org/10.1016/S1131-3587(19)30016-0","url":null,"abstract":"","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138369748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Una historia resumida. La inhibición de la PCSK9 y su desarrollo clínico 一个简短的故事。PCSK9的抑制及其临床发展
Revista Espanola de Cardiologia Suplementos Pub Date : 2017-01-01 DOI: 10.1016/S1131-3587(19)30011-1
José López-Sendón, Almudena Castro, Regina Dalmau
{"title":"Una historia resumida. La inhibición de la PCSK9 y su desarrollo clínico","authors":"José López-Sendón,&nbsp;Almudena Castro,&nbsp;Regina Dalmau","doi":"10.1016/S1131-3587(19)30011-1","DOIUrl":"10.1016/S1131-3587(19)30011-1","url":null,"abstract":"<div><p>Hypercholesterolaemia is one of the major cardiovascular risk factors; however, conventional treatment with diet, exercise and cholesterol-lowering drugs are insufficient to control low-density lipoprotein (LDL) cholesterol in a significant number of patients. Inhibition of the PCSK9 protein by using specific monoclonal antibodies increases the number of LDL cholesterol receptors in the hepatocyte, contributing to LDL destruction. The use of these drugs, whether as monotherapy or in combination with statins and ezetimibe, significantly reduces LDL cholesterol, allowing LDL cholesterol levels in most patients to be maintained within limits recommended by clinical practice guidelines. To determine their clinical efficacy, 3 multicenter trials of morbidity and mortality have been conducted with alirocumab, evolocumab and bococizumab. The trial involving evolocumab, a fully human monoclonal antibody, demonstrated a significant reduction of the primary efficacy endpoint, including cardiovascular mortality, myocardial infarction, stroke, unstable angina or myocardial revascularisation. However, no clinical benefit was observed with bococizumab (a humanised but not fully human monoclonal antibody), probably due to a decrease in efficacy secondary to the formation of anti-drug antibodies. This new therapeutic option is already used in clinical practice and is considered a new advance in the prevention of cardiovascular disease.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56634291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Medicina traslacional, tratamiento de las dislipemias y prevención secundaria: conclusiones 转化医学、血脂异常的治疗和二级预防:结论
Revista Espanola de Cardiologia Suplementos Pub Date : 2017-01-01 DOI: 10.1016/S1131-3587(19)30014-7
Manuel Anguita Sánch
{"title":"Medicina traslacional, tratamiento de las dislipemias y prevención secundaria: conclusiones","authors":"Manuel Anguita Sánch","doi":"10.1016/S1131-3587(19)30014-7","DOIUrl":"10.1016/S1131-3587(19)30014-7","url":null,"abstract":"","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56634508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factores determinantes del riesgo isquémico del paciente tras un infarto agudo de miocardio 急性心肌梗死后缺血性风险的决定因素
Revista Espanola de Cardiologia Suplementos Pub Date : 2017-01-01 DOI: 10.1016/S1131-3587(19)30018-4
Juan M. Ruiz-Nodar , Emad Abu-Assi
{"title":"Factores determinantes del riesgo isquémico del paciente tras un infarto agudo de miocardio","authors":"Juan M. Ruiz-Nodar ,&nbsp;Emad Abu-Assi","doi":"10.1016/S1131-3587(19)30018-4","DOIUrl":"10.1016/S1131-3587(19)30018-4","url":null,"abstract":"<div><p>The assessment of ischemic risk in patients presenting with a myocardial infarction is crucial for helping to select (from hospital admission onwards) the best management strategy and for deciding which antiplatelet treatment will produce the greatest improvement in prognosis. Risk assessments, which have improved in recent years, provide us with quantitative indicators of the patient’s short-and long-term prognosis. This article contains a review of the different approaches to ischemic risk assessment in patients admitted with an infarction, the most commonly used risk scores, the assessment of residual risk in patients with an infarction and the identification of patients with an elevated medium-and long-term risk. It also considers how angiographic characteristics and percutaneous revascularization influence prognosis in these patients.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56634671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Importancia de la medicina traslacional: mecanismos del beneficio del tratamiento de las dislipemias y su implicación en la reducción de la placa 转化医学的重要性:血脂异常治疗的益处机制及其在减少斑块中的作用
Revista Espanola de Cardiologia Suplementos Pub Date : 2017-01-01 DOI: 10.1016/S1131-3587(19)30012-3
Mónica Domenecha , Ramón Estruch , Raúl Moreno , Manuel Anguita Sánchez
{"title":"Importancia de la medicina traslacional: mecanismos del beneficio del tratamiento de las dislipemias y su implicación en la reducción de la placa","authors":"Mónica Domenecha ,&nbsp;Ramón Estruch ,&nbsp;Raúl Moreno ,&nbsp;Manuel Anguita Sánchez","doi":"10.1016/S1131-3587(19)30012-3","DOIUrl":"10.1016/S1131-3587(19)30012-3","url":null,"abstract":"<div><p>Cardiovascular disease continues to be the most common cause of morbidity and mortality in western countries. Hyperlipidaemia, including hypercholesterolemia and atherogenic dyslipidaemia, is one the main risk factors for atherosclerotic heart disease. Routine therapies for hypercholesterolaemia include HMG-CoA reductase inhibitors (statins), NPC1L1 inhibitors (ezetimibe), phytosterols, menacholyne K, bile salt sequestrants and PCSK9 inhibitors. New drugs under development are CEPT inhibitors, antisense oligonucleotides and inhibitors of microsomal triglyceride transfer protein. The association between hyperlipidaemia and atherosclerosis is well documented. Arterial wall remodelling, described by Glagov more than 3 decades ago, is a key phenomenon in coronary artery atherosclerosis. When atherosclerotic plaque increases, artery diameter also increases to compensate lumen reduction. It is only in the final stage of the process, when the increase in diameter is unable to compensate for plaque growth, that clinical ischaemia develops. In this article, we review the mechanisms of action of drugs used for the treatment of dyslipidaemia, and the role of lipid level control in plaque reversal.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82667296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Avances en el control lipídico, de la teoría a la práctica. El reto de la medicina traslacional 脂质控制的进展,从理论到实践。转化医学的挑战
Revista Espanola de Cardiologia Suplementos Pub Date : 2017-01-01 DOI: 10.1016/S1131-3587(19)30013-5
Juan Cosin Sales , Regina Dalmau , Manuel Anguita Sánchez
{"title":"Avances en el control lipídico, de la teoría a la práctica. El reto de la medicina traslacional","authors":"Juan Cosin Sales ,&nbsp;Regina Dalmau ,&nbsp;Manuel Anguita Sánchez","doi":"10.1016/S1131-3587(19)30013-5","DOIUrl":"10.1016/S1131-3587(19)30013-5","url":null,"abstract":"<div><p>Lipid control is one of the pillars of secondary prevention, but despite multiple evidence showing that the risk of new cardiovascular events decreases with lower low-density lipoprotein cholesterol (LDL-C) levels, this remains the most poorly controlled risk factor in our patients. The development of new drugs, such as PCSK9 inhibitors, will help us to improve this problem, but programmes that improve the continuity of care between cardiologists and primary care physicians are also very important. Although good drugs are available, lipid goals will not be achieved unless they are used in our patients. Despite the clinical development of lipid-lowering therapies in the last few years, there is currently an important gap between the evidence generated by many clinical trials, reflected in the clinical practice guidelines, and its clinical application in our patients, contributing to the fact that a significant number of patients with established cardiovascular disease do not achieve lipid control targets, and consequently continue to be at high risk or have recurrent events. To narrow this gap, it seems necessary to critically analyse the main barriers and to develop strategies to solve these problems. Basic and clinical investigators, cardiologists and primary care physicians, other health professionals, scientific societies and health authorities working together will contribute to close the gap and to improve cardiovascular health outcomes.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56634469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Novedades en la evaluación del riesgo hemorrágico del paciente con cardiopatía isquémica 缺血性心脏病患者出血风险评估的新进展
Revista Espanola de Cardiologia Suplementos Pub Date : 2017-01-01 DOI: 10.1016/S1131-3587(19)30019-6
Sergio Raposeiras Roubín , Albert Ariza Solé
{"title":"Novedades en la evaluación del riesgo hemorrágico del paciente con cardiopatía isquémica","authors":"Sergio Raposeiras Roubín ,&nbsp;Albert Ariza Solé","doi":"10.1016/S1131-3587(19)30019-6","DOIUrl":"10.1016/S1131-3587(19)30019-6","url":null,"abstract":"<div><p>The assessment of bleeding risk is the limiting factor in determining the balance between the risk of ischemia and hemorrhage, which must be determined before the type and duration of antithrombotic therapy can be selected. The best data for estimating bleeding risk are available during hospitalization and several suitable risk scores have been developed and have undergone extensive validation and comparison. The CRUSADE bleeding score appears to be the most useful. In addition, several risk scores for assessing bleeding risk over the medium to long term after hospital discharge or after coronary artery revascularization have recently appeared, such as the PRECISE-DAPT (PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy), the PARIS (Patterns of non-Adherence to Anti-Platelet Regimens in Stented Patients), the DAPT (Dual AntiPlatelet Therapy) and the TRILOGY-ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) risk scores. All have demonstrated reasonably good predictive power but they have some important limitations, which mean that they will have to undergo comparative validation studies before their usefulness can be extended to patients treated with new antiplatelet agents (e.g. ticagrelor and prasugrel) and oral anticoagulants, including both vitamin K antagonists and direct-acting oral anticoagulants.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56634746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Introducción 导言
Revista Espanola de Cardiologia Suplementos Pub Date : 2017-01-01 DOI: 10.1016/S1131-3587(19)30008-1
José López-Sendón
{"title":"Introducción","authors":"José López-Sendón","doi":"10.1016/S1131-3587(19)30008-1","DOIUrl":"https://doi.org/10.1016/S1131-3587(19)30008-1","url":null,"abstract":"","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138421693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Indicación del tratamiento con doble antiagregación más allá del año. A quién y por qué 一年以上双抗聚集治疗的适应症。给谁,为什么
Revista Espanola de Cardiologia Suplementos Pub Date : 2017-01-01 DOI: 10.1016/S1131-3587(19)30020-2
Juan Carlos Gómez-Polo , David Vivas , Inmaculada Roldán
{"title":"Indicación del tratamiento con doble antiagregación más allá del año. A quién y por qué","authors":"Juan Carlos Gómez-Polo ,&nbsp;David Vivas ,&nbsp;Inmaculada Roldán","doi":"10.1016/S1131-3587(19)30020-2","DOIUrl":"10.1016/S1131-3587(19)30020-2","url":null,"abstract":"<div><p>Currently, dual antiplatelet therapy with acetylsalicylic acid and an ADP-P2Y12 receptor inhibitor is regarded as the treatment of choice for patients with acute coronary syndrome and for those who have undergone percutaneous coronary intervention with coronary stent implantation. Clinical practice guidelines recommend that dual antiplatelet therapy is maintained for 12 months in most contexts and prolonging therapy beyond this time remains controversial. The aim of this article was to present a review of the literature available on which patients would benefit from the prolongation of dual antiplatelet therapy.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56634353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Escalas de evaluación del riesgo tromboembólico y hemorrágico en la fibrilación auricular 评估房颤血栓栓塞和出血性风险的量表
Revista Espanola de Cardiologia Suplementos Pub Date : 2016-01-01 DOI: 10.1016/S1131-3587(16)30011-5
Javier Pérez-Copete , María Asunción Esteve-Pastor , Vanessa Roldán , Mariano Valdés , Francisco Marín
{"title":"Escalas de evaluación del riesgo tromboembólico y hemorrágico en la fibrilación auricular","authors":"Javier Pérez-Copete ,&nbsp;María Asunción Esteve-Pastor ,&nbsp;Vanessa Roldán ,&nbsp;Mariano Valdés ,&nbsp;Francisco Marín","doi":"10.1016/S1131-3587(16)30011-5","DOIUrl":"10.1016/S1131-3587(16)30011-5","url":null,"abstract":"<div><p>Atrial fibrillation is the most prevalent cardiac arrhythmia in the general population. Its presence increases the risk of thromboembolic events five-fold. Antithrombotic therapy reduces this risk, but increases the risk of bleeding, with intracranial bleeding being the most feared complication. However, the risk varies between patients and, as a result, various thromboembolic risk scores have been developed in recent years (e.g. the CHADS<sub>2</sub>, CHA<sub>2</sub>DS<sub>2</sub>-VASc and ATRIA scores). The CHA<sub>2</sub>DS<sub>2</sub>-VASc score is recommended by clinical practice guidelines to help optimize antithrombotic therapy in patients with atrial fibrillation. In addition, these guidelines also recommend that both thromboembolic risk and the risk of bleeding should be assessed. A number of risk models have been proposed for assessing the bleeding risk in these patients (e.g. the HEMORR<sub>2</sub>HAGES, HAS-BLED, ATRIA and ORBIT-AF scores), but currently the majority of guidelines recommend the HAS-BLED score. Above all, it is essential that the net clinical benefit of antithrombotic therapy is assessed: the expected benefit of anticoagulation therapy should outweigh the expected harm caused by possible bleeding. Nevertheless, the ability of both thromboembolic and bleeding risk scores to predict clinical events is only moderate. Consequently, alternative approaches, such as the use of biomarkers (e.g. D-dimer, von Willebrand factor and GDF-15), could help evaluate the thromboembolic risk in individual patients with atrial fibrillation.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30011-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"56633720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信